Compounds for the Treatment of Hepatitis C

A compound of formula I

• where:
• R1 is phenyl substituted with 1 CON(R5)(R6);
• and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkyloxy, alkoxyalkyloxy, benzyloxy, (CON(R7)(R8))alkyloxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, (carboxy)alkenyl, (alkoxycarbonyl)alkenyl, alkylcarboxamido, alkoxycarboxamido, alkylsulfamido, (alkylsulfamido)alkyl, Ar2, and SO2N(R7)(R8);
• and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo;
• nitro;
• alkyl;
• cycloalkyl;
• haloalkyl;
• aminoalkyl;
• hydroxyalkyl;
• alkoxyalkyl;
• hydroxy;
• alkoxy;
• O(R9);
• cycloalkoxy;
• amino;
• alkylamino;
• dialkylamino;
• alkylcarboxamido;
• alkoxycarboxamido;
• alkoxyalkylcarboxamido;
• furanyl, thienyl, pyrazolyl substituted with 0-2 alkyl substituents;
• pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents;
• pyrimidinyl;
• pyrimidinedionyl;
• aminopyrimidinyl;
• indolyl;
• isoquinolinyl;
• and phenyl substituted with 0-2 substituents selected from the group consisting of halo, alkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarboxamido, carboxyalkenyl, and phenyl;
• R2 is hydrogen, halo, nitro, amino, phenyl, or (R10)(R11)N;
• R3 is cyano, alkoxycarbonyl, (cycloalkyl)oxycarbonyl, (alkylsulfonyl)aminocarbonyl, CON(R12)(R13), (R12)(R13)NCONH, triazolyl, thiazolyl, or tetrazolyl;
• R4 is phenyl substituted with 0-2 halo, alkoxy, phenoxy, or halophenoxy substituents;
• R5 is
• R6 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;
• R7 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, or benzyl;
• R8 is hydrogen or alkyl;
• or R7 and R8 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;
• R9 is haloalkyl, cyanoalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, (R16)alkyl, (Ar3)alkyl, alkynyl, or aminocycloalkyl;
• R10 is hydrogen, alkyl, or alkylsulfonyl;
• R11 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or alkylsulfonyl;
• R12 is hydrogen, alkyl, or cycloalkyl;
• R13 is hydrogen, alkyl, or cycloalkyl;
• or R12 and R13 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;
• R14 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;
• R15 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;
• or R14 and R15 taken together is ethylene, propylene, butylene, pentylene, or hexylene;
• R16 is CONH2, H2NCONH, dibenzylamino, phthalimido, amino, alkylamino, dialkylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl where azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 alkyl or alkoxycarbonyl substituents;
• R17 is hydrogen, halo, alkyl, or alkoxy;
• R18 is hydrogen, halo, alkyl, or alkoxy;
• Ar1 is azaindolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, oxazolopyridinyl, imidazopyridinyl, quinazolinyl, pyridopyrimidinyl or naphthyridinyl, and is substituted with 0-2 substituents selected from halo, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aminocarbonyl, pyridinyl, phenyl, halophenyl, alkylphenyl, and alkoxyphenyl;
• Ar2 is phenyl, biphenyl, or pyridinyl and is substituted with 0-2 substituents selected from halo, alkyl, cyano, hydroxy, alkoxy, and carboxy;
• and
• Ar3 is furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, indolyl, or phenyl and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, hydroxyl, and alkoxy;
• or a pharmaceutically acceptable salt thereof.